Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.2K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

884
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
884
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

140
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
140
Compartment Models: Two-Compartment Model01:20

Compartment Models: Two-Compartment Model

5.9K
The two-compartment model divides the body into central and peripheral compartments to account for varying blood perfusion rates among organs and tissues, affecting drug distribution. The central compartment includes blood and highly perfused tissues with rapid drug distribution, while the peripheral compartment contains tissues with slower drug distribution. After a single IV bolus dose, the drug concentration is high in plasma and low in tissues. The drug distribution between compartments...
5.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

21
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response: Codeine in Breast Milk: Minimal Transfer, Still Risky for Neonates.

Paediatric anaesthesia·2026
Same author

Codeine and Metabolite Concentrations in the Breastfed Neonate.

Paediatric anaesthesia·2026
Same author

Developing a Pediatric Pain Curriculum for Pediatric Anesthesia Fellows in Sub-Saharan Africa: A Delphi Study.

Paediatric anaesthesia·2026
Same author

Milk Fasting Times and Aspiration in Infants.

Paediatric anaesthesia·2026
Same author

Dabigatran in Sheep Cardiopulmonary Bypass: Reply.

Anesthesiology·2026
Same author

Individualising drug therapy in intensive care.

Anaesthesia and intensive care·2026

Related Experiment Video

Updated: Sep 7, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K

Delayed concentration effect models for dabigatran anticoagulation.

Michael P Eaton1, Sergiy M Nadtochiy1, Tatsiana Stefanos1

  • 1University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

Paediatric Anaesthesia
|June 23, 2022
PubMed
Summary
This summary is machine-generated.

This study investigated dabigatran

Keywords:
cardiopulmonary bypasscoagulationdabigatranpharmacokinetics

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.4K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K

Related Experiment Videos

Last Updated: Sep 7, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.4K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K

Area of Science:

  • Pharmacology
  • Pharmacokinetics
  • Cardiovascular Research

Background:

  • Dabigatran is an anticoagulant with potential applications in cardiopulmonary bypass.
  • Understanding its pharmacokinetic-pharmacodynamic (PK-PD) relationship is crucial for safe and effective use.
  • Previous studies have not fully elucidated the PK-PD of dabigatran in the context of cardiopulmonary bypass.

Purpose of the Study:

  • To investigate the pharmacokinetic-pharmacodynamic relationship of dabigatran's anticoagulation effect in an animal model.
  • To develop and validate a PK-PD model for dabigatran in rabbits undergoing simulated cardiopulmonary bypass conditions.
  • To provide data that can inform future preclinical and clinical studies involving dabigatran.

Main Methods:

  • Ten male New Zealand white rabbits received intravenous dabigatran (15 mg/kg).
  • Blood samples were collected at various time points for activated clotting time, thromboelastometric reaction time, and drug assay.
  • Integrated PK-PD modeling using nonlinear mixed effects, including a sigmoidal EMAX model and an effect compartment model, was employed.

Main Results:

  • A two-compartment model effectively described dabigatran pharmacokinetics.
  • The effect compartment model adequately captured pharmacodynamics for both activated clotting time and thromboelastometric reaction time.
  • Short equilibration half-times (<2 min) were observed for dabigatran's anticoagulant effect.

Conclusions:

  • The effect compartment model provided a robust description of dabigatran's pharmacodynamics.
  • The study provides essential preclinical data on dabigatran's PK-PD, applicable to humans.
  • These findings support the use of dabigatran in future animal studies related to cardiopulmonary bypass.